In summary, in this German population-based study, we have examined the impact of KMT2A-r on the clinical characteristics and outcome of pediatric AML patients, as well as the correlation of KMT2A-r with additional genetic aberrations and the expression of CSPG4 on the cell surface. This evidence concerns the gene CSPG4 and acute myeloid leukemia.